We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image
  • Published On : Jan 2022
  • Code : CMI4886
  • Pages :165
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Canine atopic dermatitis (AD) has been defined as a genetically predisposed inflammatory and pruritic allergic skin disease of dogs and cats. Atopic dermatitis in dogs is treated by using antibiotics, immunosuppressant, Janus kinase inhibitors, and monoclonal antibodies. For instance, CYTOPOINT is one of the most efficient monoclonal antibodies used for the treatment of canine atopic dermatitis. Major players operating in the global canine atopic dermatitis treatment drugs market include Zenoaq (Nippon Zenyaku Kogyo Co., Ltd.), Virbac, Elanco Animal Health, Kindred Biosciences Inc., Toray Industries, and Zoetis Inc.

Furthermore, the development of new treatment options in regenerative medicine for canine atopic dermatitis is on high demand, which provides opportunity for pharmaceutical and biotechnological companies to develop new drugs to treat AD. Cell therapy is one of the emerging treatment options in canine atopic dermatitis. Several organizations are focused on the development of cell therapy and such treatments are under clinical trials.

The global canine atopic dermatitis treatment drugs market size is estimated to be valued at US$ 765 million in 2021 and is expected to witness a CAGR of 16.5% over the forecast period (2021-2028).

Figure1. Global Canine Atopic Dermatitis Treatment Drugs Market Share (%) Analysis, By Drug Class, 2021

CANINE ATOPIC DERMATITIS TREATMENT DRUGS MARKET

To learn more about this report, request a free sample copy

Rising number of research and development activities is expected to drive growth of the global canine atopic dermatitis treatment drugs market

The rising number of research and development activities to launch various treatment therapies for canine atopic dermatitis is expected to be a major factor driving the growth of the global canine atopic dermatitis treatment drugs market in the near future. For instance, in July 2019, Kindred Biosciences, Inc., a clinical-stage biopharmaceutical company, announced positive results from its pilot study on effectiveness of KIND-016, a fully caninized (anti-canine), high-affinity monoclonal antibody targeting interleukin-31 (IL-31), for the treatment of atopic dermatitis in dogs.

A single dose of KIND-016 or placebo was administered on day 1 and the atopic dermatitis severity (Canine Atopic Dermatitis Extent and Severity Index-4 [CADESI-4 score]) was assessed on day 1, and weeks 1, 2, 3, 4, 6, and 8.

Canine Atopic Dermatitis Treatment Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

 The coronavirus (COVID-19) pandemic is the most recent outbreak, which was first reported on December 31, 2019, in Wuhan, China. In Australia, the first COVID-19 case was confirmed in late January 2020, while in New Zealand, the first case was confirmed in late February 2020.

For many allergies and diseases the environmental factors are responsible. Increasing R & D activities are expected to rise the market. In 2020, according to the research article, Veterinary Medicine and Science, for the treatment of canine atopic dermatitis the Luteolin was evaluated to study the antioxidant effect. After evaluation the Luteolin resulted as it was able to minimize the levels of IL-33, IL-6 and IL-8.

Hydroxychloroquine Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 765 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 16.5% 2028 Value Projection: US$ 1,800 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: Janus kinase inhibitors, Immunosuppressant, Monoclonal antibody, Antibiotics, Others
  • By Route of Administration: Injection, Oral, Topical
  • By Distribution channel: Hospitals and Clinics, Online pharmacies, Retail pharmacies
Companies covered:

Zeotis Inc, Elanco Animal Health Incorporated, Virbac, Kindred Biosciences, Inc., Nippon Zenyaku Kogyo Co., Ltd., Bioiberica S.A.U., Dechra Pharmaceuticals Plc, and Toray Industries, Inc.

Growth Drivers:
  • Rising R&D activities and increasing number of approvals from regulatory agencies for novel therapies
  • Increasing pet ownership and healthcare expenditure
Restraints & Challenges:
  • High cost associated with canine atopic dermatitis treatment and limited pet health insurance coverage

Global Canine Atopic Dermatitis Treatment Drugs Market- Restraints

Lack of pet health insurance and high cost of treatment are major factors due to which pet owners have to pay the treatment cost. Thus, lack of pet health insurance is expected to hamper the global canine atopic dermatitis treatment drugs market growth.

The pet health benefit plans are expected to allow pet owners to take advantage of discounts on prescriptions, vet visits, and cancer treatments, however, the government intervention for pet health insurance is less prevalent than for human health insurance.

Global Canine Atopic Dermatitis Treatment Drugs Market- Regional Insights

On the basis of region, the global canine atopic dermatitis treatment drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global canine atopic dermatitis treatment drugs market over the forecast period, owing to the increasing prevalence of canine atopic dermatitis in the region.

Asia Pacific is expected to witness rapid growth in the global canine atopic dermatitis treatment drugs market, owing to the presence of various animal health companies, which are focusing on canine atopic dermatitis research. For instance, in February 2019, Immunomic Therapeutics, Inc., a Maryland-based biotechnology company, declared that the company granted an exclusive license to develop and commercialize its investigational DNA vaccine, ITI-002, for canine atopic dermatitis and other companion animal allergies to a Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan).

Figure 2. Global Canine Atopic Dermatitis Treatment Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2028

CANINE ATOPIC DERMATITIS TREATMENT DRUGS MARKET

To learn more about this report, request a free sample copy

Global Canine Atopic Dermatitis Treatment Drugs Market - Competitive Landscape

Key players operating in the global canine atopic dermatitis treatment drugs market include Zoetis Inc., Elanco Animal Health Incorporated, Virbac, Kindred Biosciences, Inc., Nippon Zenyaku Kogyo Co., Ltd. (ZENOAQ), Bioiberica S.A.U, Dechra Pharmaceuticals PLC, and Toray Industries, Inc.

Frequently Asked Questions

The global canine atopic dermatitis treatment drugs market is estimated to be valued at US$ 765 million in 2021 and is expected to exhibit a CAGR of 16.5% over the forecast period (2021-2028).

Rising R&D activities and increasing number of approvals from regulatory agencies for novel therapies, increasing pet ownership and healthcare expenditure, and emerging stem cell therapies for treatment of canine atopic dermatitis are the major factors, which are expected to drive the market growth over the forecast period. 

North America holds the largest market share in the market.

Janus Kinase Inhibitors segment holds the major market share in the market.

Major factors hampering growth of the market include high cost associated with canine atopic dermatitis treatment and limited pet health insurance coverage.

Major players operating in the market include Zeotis Inc, Elanco Animal Health Incorporated, Virbac, Kindred Biosciences, Inc., Nippon Zenyaku Kogyo Co., Ltd., Bioiberica S.A.U., Dechra Pharmaceuticals Plc, and Toray Industries, Inc.

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo